Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease

To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders.

[1]  N. Hattori,et al.  Metabolomics‐based identification of metabolic alterations in PARK2 , 2019, Annals of clinical and translational neurology.

[2]  Xiao-hong Liu,et al.  Association between serum uric acid level and multiple system atrophy: A meta-analysis , 2018, Clinical Neurology and Neurosurgery.

[3]  Nobutaka Hattori,et al.  Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease , 2018, Neurology.

[4]  M. Kuwahata,et al.  Potential Role of Amino Acid/Protein Nutrition and Exercise in Serum Albumin Redox State , 2017, Nutrients.

[5]  Zi-rong Li,et al.  The significance of uric acid in the diagnosis and treatment of Parkinson disease , 2017, Medicine.

[6]  Nobutaka Hattori,et al.  Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease , 2017, Scientific Reports.

[7]  H. Ikeda,et al.  Evaluation of human nonmercaptalbumin as a marker for oxidative stress and its association with various parameters in blood , 2017, Journal of clinical biochemistry and nutrition.

[8]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[9]  J. Melendez,et al.  Redox control of senescence and age-related disease , 2016, Redox biology.

[10]  M. Maes,et al.  Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson’s disease and its progression: Disease and staging biomarkers and new drug targets , 2016, Neuroscience Letters.

[11]  F. Carrillo,et al.  Low serum uric acid levels in progressive supranuclear palsy , 2016, Movement disorders : official journal of the Movement Disorder Society.

[12]  J. Baldissarelli,et al.  Iron and Oxidative Stress in Parkinson’s Disease: An Observational Study of Injury Biomarkers , 2016, PloS one.

[13]  Bertrand Friguet,et al.  Mechanisms of Ageing and Development Mark-age Biomarkers of Ageing , 2022 .

[14]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[15]  Richard Wade-Martins,et al.  Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. , 2015, Trends in biochemical sciences.

[16]  C. Klein,et al.  iPS models of Parkin and PINK1. , 2015, Biochemical Society transactions.

[17]  Nobutaka Hattori,et al.  Identification of novel biomarkers for Parkinson's disease by metabolomic technologies , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  J. O'Callaghan,et al.  Biomarkers of Parkinson's disease: present and future. , 2015, Metabolism: clinical and experimental.

[19]  E. Bézard,et al.  Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives , 2014, The Lancet.

[20]  R. Stauber,et al.  Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. , 2013, Journal of hepatology.

[21]  G. Aldini,et al.  Human serum albumin cysteinylation is increased in end stage renal disease patients and reduced by hemodialysis: mass spectrometry studies , 2013, Free radical research.

[22]  S. Studenski,et al.  The Risk of Parkinson Disease Associated with Urate in a Community-Based Cohort of Older Adults , 2011, Neuroepidemiology.

[23]  N. Hattori,et al.  PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy , 2010, FEBS letters.

[24]  N. Hattori,et al.  Pathogenesis of familial Parkinson’s disease: new insights based on monogenic forms of Parkinson’s disease , 2009, Journal of neurochemistry.

[25]  Xuemei Huang,et al.  Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. , 2009, American journal of epidemiology.

[26]  S. Era,et al.  Resolution of human mercapt- and nonmercaptalbumin by high-performance liquid chromatography. , 2009, International journal of peptide and protein research.

[27]  R. Youle,et al.  Parkin is recruited selectively to impaired mitochondria and promotes their autophagy , 2008, The Journal of cell biology.

[28]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[29]  E. Bourdon,et al.  The antioxidant properties of serum albumin , 2008, FEBS letters.

[30]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[31]  N. Hattori,et al.  Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease , 2005, Neurology.

[32]  Werner Poewe,et al.  Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. , 2005, The American journal of pathology.

[33]  Laurent Gerbaud,et al.  Impact of the motor complications of Parkinson's disease on the quality of life , 2005, Movement disorders : official journal of the Movement Disorder Society.

[34]  A. Manning-Boğ,et al.  Environmental factors in Parkinson's disease. , 2002, Neurotoxicology.

[35]  S. Augood,et al.  Evidence for Oxidative Stress in the Subthalamic Nucleus in Progressive Supranuclear Palsy , 1999, Journal of neurochemistry.

[36]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[37]  E. Floor,et al.  Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.

[38]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Yasuda,et al.  Increased oxidized form of human serum albumin in patients with diabetes mellitus. , 1992, Diabetes research and clinical practice.

[40]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Y. Yatomi,et al.  A simple, rapid and validated high-performance liquid chromatography method suitable for clinical measurements of human mercaptalbumin and non-mercaptalbumin , 2018, Annals of clinical biochemistry.

[42]  J. Volkmann,et al.  Parkinson disease , 2017, Nature Reviews Disease Primers.